LUPIN LIMITED
RESULTS FOR Q3 FY 2013-14 (DEC,2013)
Lupin
Limited has posted excellent Results for the third quarter ending
December,2013.
The
Results are in the table below. Net Sales has grown 21% YoY, whereas, Net
Profit has grown 41% YoY.
On
a Rs.2 FV, the Diluted EPS is Rs.10.58. The annualized EPS comes to Rs.42.32.
At the current Market price of around Rs.922, the PE Ratio comes to 21.8. As we
can see from the statements of the company, the future of Lupin is brighter in
future.
RESULTS TABLE
|
LUPIN
LTD
|
Q3FY14
|
%DifQoQ
|
Q2FY14
|
%Dif
YoY
|
Q3FY13
|
|
Net
Sales
|
2983
|
13.38
|
2631
|
20.97
|
2466
|
|
Other
Optg Income
|
39
|
8.33
|
36
|
11.43
|
35
|
|
Total
Income
|
3022
|
13.27
|
2668
|
20.83
|
2501
|
|
total
Exp
|
2312
|
11.74
|
2069
|
17.66
|
1965
|
|
Profit
from Oprtns
|
710
|
18.53
|
599
|
32.46
|
536
|
|
OtherIncome
|
32
|
-60.49
|
81
|
18.52
|
27
|
|
Finance
Costs
|
4
|
-20
|
5
|
-50
|
8
|
|
PBT
|
738
|
9.33
|
675
|
32.97
|
555
|
|
Tax
|
254
|
-1.93
|
259
|
19.81
|
212
|
|
Net
Profit
|
484
|
16.07
|
417
|
41.11
|
343
|
|
Mino.Intt
|
8
|
-27.27
|
11
|
0
|
8
|
|
Net
profit
|
476
|
17.24
|
406
|
41.67
|
336
|
|
Equity
|
89.65
|
0.06
|
89.6
|
0.19
|
89.48
|
|
FV
|
2
|
0
|
2
|
0
|
2
|
|
BasicEPS
|
10.63
|
17.2
|
9.07
|
41.92
|
7.49
|
|
Dil.EPS
|
10.58
|
17.17
|
9.03
|
41.82
|
7.46
|
|
R&D
Exp
|
271
|
24.88
|
217
|
13.87
|
238
|
OTHER NEWS
ON LUPIN:
Lupin Limited has announced the acquisition of
Netherlands-based Nanomi BV. With this, the company has made its foray into the
technology-intensive injectables space.
Nanomi, the Dutch life
sciences company, provides advanced drug delivery products, enabled by its
monosphere technology. The company, founded in 2004, has expertise in drug
delivery, molecular imaging and diagnostics.
Nanomi has patented
technology platforms to develop complex injectable products. It has a rich
talent pool of scientists who would be backed by Lupin’s global R&D and
manufacturing teams, said a Lupin statement.
"With the use of
Nanomi's proprietary technology platform, Lupin would be able to make
significant in-roads into the niche area of complex injectables," Lupin CEO,
Vinita Gupta said.
FEATURES
OF Q3 FY 14 RESULTS :
US is the biggest
part of Lupin’s business. It constitutes 45 % of its revenues. India is about
24-25 %. Japan is about 11-12 %.
US grew by 31 % in
rupee terms over the quarter. India grew by 14 %. API business which is about
10 % grew by 24-25 %. So, it is an all round growth but it is obviously the US
that led the growth. Two parts in the US, one part was launch of some pretty
interesting products. Lupin had five product launches, four of them which are
either semi-exclusively or completely exclusive opportunities. Trizivir and
Zymaxid were launched after successful patent challenge wins. There is no
authorized generic even in the market. So, these are very interesting
opportunities. The inline products, the products that Lupin has been selling
for a while in the US also grew rather nicely.
Considering these
news from Lupin, it can be seen that future quarters will be equally growth oriented for Lupin.
*
* * E
N D *
* *
No comments:
Post a Comment